Andrew Saik

Insider Reports History

Location
Chesterbrook, PA
Signature
/s/ Jared Freedberg, as attorney-in-fact for Andrew Saik
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Andrew Saik:

Company Role Class Num Shares Value Price $ Report Date Ownership
ARVINAS, INC. Chief Financial Officer Common Stock 164,401 $1,251,091 $7.61 24 Jun 2025 Direct
ARVINAS, INC. Chief Financial Officer Stock Option (right to buy) 91,000 $1,199,360 $16.00 09 May 2025 Direct
VYNE Therapeutics Inc. Chief Financial Officer Common Stock 116,468 $265,547 $2.28 28 May 2021 Direct
Milestone Pharmaceuticals Inc. Director Stock Option (right to buy) 40,000 10 Jun 2025 Direct
INTERCEPT PHARMACEUTICALS, INC. EVP & Chief Financial Officer Common Stock 0 $19.00 08 Nov 2023 Direct
INTERCEPT PHARMACEUTICALS, INC. EVP & Chief Financial Officer Option to Purchase Common Stock 0 08 Nov 2023 Direct

Insider Reports Filed by Andrew Saik

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ARVN ARVINAS, INC. 24 Jun 2025 1 -$43,377 4 Chief Financial Officer 24 Jun 2025, 16:08
MIST Milestone Pharmaceuticals Inc. 10 Jun 2025 1 $0 4 Director 12 Jun 2025, 16:19
ARVN ARVINAS, INC. 09 May 2025 2 $0 4 Chief Financial Officer 13 May 2025, 17:17
ARVN ARVINAS, INC. 13 Feb 2025 2 $0 4 Chief Financial Officer 18 Feb 2025, 19:59
MIST Milestone Pharmaceuticals Inc. 28 Aug 2024 1 $0 4 Director 29 Aug 2024, 16:15
MIST Milestone Pharmaceuticals Inc. 15 Jul 2024 1 $0 4 Director 17 Jul 2024, 16:17
MIST Milestone Pharmaceuticals Inc. 15 Jul 2024 0 $0 3 Director 17 Jul 2024, 16:16
ARVN ARVINAS, INC. 24 Jun 2024 2 $0 4 Chief Financial Officer 26 Jun 2024, 16:20
ARVN ARVINAS, INC. 24 Jun 2024 0 $0 3 Chief Financial Officer 26 Jun 2024, 16:19
/report/000110465923117093-saik-andrew-2023-11-08 INTERCEPT PHARMACEUTICALS, INC. 08 Nov 2023 5 -$1,297,035 4 EVP & Chief Financial Officer 13 Nov 2023, 14:40
/report/000110465923103508-saik-andrew-2023-09-21 INTERCEPT PHARMACEUTICALS, INC. 21 Sep 2023 1 -$9,806 4 EVP & Chief Financial Officer 25 Sep 2023, 16:01
/report/000110465923074233-saik-andrew-2023-06-21 INTERCEPT PHARMACEUTICALS, INC. 21 Jun 2023 1 -$10,660 4 EVP & Chief Financial Officer 23 Jun 2023, 16:04
/report/000110465923036043-saik-andrew-2023-03-21 INTERCEPT PHARMACEUTICALS, INC. 21 Mar 2023 1 -$12,899 4 EVP & Chief Financial Officer 23 Mar 2023, 16:01
/report/000110465923008588-saik-andrew-2023-01-27 INTERCEPT PHARMACEUTICALS, INC. 27 Jan 2023 2 $0 4 EVP & Chief Financial Officer 31 Jan 2023, 15:05
/report/000110465923000337-saik-andrew-2022-12-31 INTERCEPT PHARMACEUTICALS, INC. 31 Dec 2022 1 -$8,882 4 EVP & Chief Financial Officer 03 Jan 2023, 15:04
/report/000110465922129883-saik-andrew-2022-12-21 INTERCEPT PHARMACEUTICALS, INC. 21 Dec 2022 1 -$12,194 4 EVP & Chief Financial Officer 23 Dec 2022, 15:03
/report/000110465922102662-saik-andrew-2022-09-21 INTERCEPT PHARMACEUTICALS, INC. 21 Sep 2022 1 -$13,484 4 EVP & Chief Financial Officer 23 Sep 2022, 16:02
/report/000110465922073886-saik-andrew-2022-06-21 INTERCEPT PHARMACEUTICALS, INC. 21 Jun 2022 1 -$45,327 4 EVP & Chief Financial Officer 23 Jun 2022, 16:01
/report/000110465922009563-saik-andrew-2022-01-27 INTERCEPT PHARMACEUTICALS, INC. 27 Jan 2022 2 $0 4 EVP & Chief Financial Officer 31 Jan 2022, 15:16
/report/000110465921084279-saik-andrew-2021-06-21 INTERCEPT PHARMACEUTICALS, INC. 21 Jun 2021 2 $0 4 EVP & Chief Financial Officer 22 Jun 2021, 19:01
/report/000110465921084277-saik-andrew-2021-06-21 INTERCEPT PHARMACEUTICALS, INC. 21 Jun 2021 0 $0 3 EVP & Chief Financial Officer 22 Jun 2021, 19:00
VYNE VYNE Therapeutics Inc. 28 May 2021 1 +$10,130 4 Chief Financial Officer 02 Jun 2021, 16:31